The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (accRCC): Results from cohort A of KEYNOTE-427.
 
David F. McDermott
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; exelixis; Genentech/Roche; Merck; Novartis; Pfizer; X4 Pharma
Research Funding - Prometheus (Inst)
 
Jae-Lyun Lee
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Novartis; Pfizer
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Eisai
Research Funding - Bristol-Myers Squibb; Exelixis; Janssen; Novartis; Pfizer; Roche/Genentech
 
Cezary Szczylik
No Relationships to Disclose
 
Frede Donskov
Research Funding - Ipsen (Inst); Novartis (Inst); Pfizer (Inst)
 
Jahangeer Malik
No Relationships to Disclose
 
Boris Yakovlevich Alekseev
Research Funding - Astellas Pharma; AstraZeneca; Janssen; Merck; Roche
 
James M. G. Larkin
Honoraria - Bristol-Myers Squibb; Eisai; EUSA Pharma; GlaxoSmithKline; MSD; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Sectra
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; EUSA Pharma; GlaxoSmithKline; MSD; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Sectra
Research Funding - Bristol-Myers Squibb (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis; Pfizer; Roche/Genentech
 
Vsevolod Borisovich Matveev
No Relationships to Disclose
 
Rustem Airatovich Gafanov
No Relationships to Disclose
 
Piotr Tomczak
No Relationships to Disclose
 
Scott S. Tykodi
Consulting or Advisory Role - Bristol-Myers Squibb; Calithera Biosciences
Research Funding - Argos Therapeutics (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Jounce Therapeutics (Inst); Merck Sharp & Dohme (Inst); Nektar (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Prometheus (Inst)
 
Poul F. Geertsen
Research Funding - Novartis (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis; Pfizer
 
Pawel J. Wiechno
Honoraria - Astellas Pharma; Bayer; Pfizer
Consulting or Advisory Role - Ipsen; Roche
Travel, Accommodations, Expenses - Astellas Pharma; Pfizer
 
Sang Joon Shin
No Relationships to Disclose
 
Frederic Pouliot
Honoraria - Abbvie; Amgen; Astellas Pharma; Janssen; Sanofi
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; Janssen; Sanofi
Speakers' Bureau - Sanofi
Research Funding - Astellas Pharma; AstraZeneca; Sanofi
Travel, Accommodations, Expenses - Amgen; Sanofi
 
Teresa Alonso Gordoa
No Relationships to Disclose
 
Wenting Li
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Rodolfo F. Perini
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Charles Schloss
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Michael B. Atkins
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Acceleron Pharma; Aduro Biotech; Agenus; Alexion Pharmaceuticals; Argos Therapeutics; Array BioPharma; AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Celldex; Eisai; Exelixis; Genentech; Glactone Pharma; Idera; Merck; Nektar; Novartis; Peleton; Pfizer; X4 Pharma